Neuromyelitis Optica Market SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)
Neuromyelitis Optica Market is segemented By Therapies (SOLIRIS, UPLIZNA, ULTOMIRIS, ENSPRYNG, Others), By Diagnosis and Treatment Algorithm (Acute Phase TreatmentsChronic Immunosuppressive Therapies), By Epidemology (Prevalent Cases, Gender-Specific Cases, Regional Differences), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa). The report offers the value (in USD billion) for the above-mentioned segments.
Neuromyelitis Optica Market Size
Market Size in USD
CAGR10.3%
| Study Period | 2024 - 2031 |
| Base Year of Estimation | 2023 |
| CAGR | 10.3% |
| Market Concentration | High |
| Major Players | Alexion Pharmaceuticals, AstraZeneca, Mitsubishi Chemical Group Corporation, Genetech / F.Hoffman-La Roche, Sanofi |
please let us know !
Neuromyelitis Optica Market Analysis
The Neuromyelitis Optica Market is estimated to be valued at USD 1.03 Billion in 2024 and is expected to reach USD 2.04 Billion by 2031, growing at a compound annual growth rate (CAGR) of 10.3% from 2024 to 2031. The increasing prevalence of neuromyelitis optica across the globe and rising demand for treating the condition is fueling the growth of the market. Moreover, the growing healthcare expenditure and increasing awareness about the neuromyelitis optica disease is also driving the demand for drugs and therapies used in the treatment.
The market is expected to witness positive growth over the forecast period owing to ongoing development of novel drugs and therapeutic strategies for neuromyelitis optica. Many pharmaceutical players are strongly focused on research and development of neuromyelitis optica treatment and this is further expected to create new opportunities. Additionally, increasing approval of drugs by regulatory bodies is also projected to support the market expansion through 2031.